BOSTON ( TheStreet) -- TheStreet's 2012 FDA Drug Approval Contest is in full swing, with 23 of the 59 contestants a perfect 4-0 so far. The four drugs approved by FDA -- from Amylin ( AMLN), Vertex ( VRTX), Roche- Curis ( CRIS) and Teva ( TEVA)- BioSante ( BPAX) -- have been relative layups. The challenging drug approval decisions lie ahead, starting tomorrow with Corcept Therapeutics ( CORT) and its Korlym therapy for Cushing's Syndrome. This is where the contest should start to get interesting. Forty-six percent of contestants are predicting an FDA rejection of Korlym versus 42% who are forecasting approval. The remaining 10% predict an FDA delay. Like I said, the Korlym approval decision is set for Friday. Of the 23 contestants with perfect 4-0 records so far (I'm included in this illustrious group), 52% say Korlym gets rejected; 35% predict approval and 13% say no decision. Here's how the approval predictions play out for the remaining drug approval decisions: Columbia Labs ( CBRX): Approval 5%; Rejection 88%; No decision 7%. Discovery Labs ( DSCO): Approval 47%; Rejection 49%; No decision 3%. Astex Pharma ( ASTX): Approval 36%; Rejection 46%; No decision 18%. NeurogesX ( NSGX): Approval 47%; Rejection 46%; No decision 7%. MAP Pharma ( MAPP): Approval 37%; Rejection 59%; No decision 3%. Affymax ( AFFY): Approval 68%; Rejection 22%; No decision 10%. Chelsea Therapeutics ( CHTP): Approval 53%; Rejection 43%; No decision 3%. Vivus ( VVUS) (Qnexa): Approval 49%; Rejection 39%; No decision 12%. Amgen ( AMGN): Approval 53%; Rejection 42%; No decision 5%. Vivus (Avanafil): Approval 76%; Rejection 19%; No decision 5%. Note: Cell Therapeutics ( CTIC) was removed from the contest given the withdrawal of the pixantrone filing. One more note: One contestant has yet to get a single drug-approval decision correct. He/she is a lousy 0-4. I'll spare this person any further embarrassment by withholding their identity. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.